Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety

Abstract

Objective:To compare the efficacy and safety of rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease (GERD).Materials and Methods:A randomized, single-blinded, outdoor-based clinical study was conducted on 60 patients of mild-to-moderate erosive GERD. After baseline clinical assessment and investigations, rabeprazole (40 mg) was prescribed to 30 patients and esomeprazole (40 mg) to another 30 patients for 4 weeks. The efficacy variables were change in GERD symptom scoring, endoscopic findings, and Quality of Life in Reflux and Dyspepsia (QOLRAD) scoring over 4 weeks.Result:Heartburn, acid regurgitation, and overall GERD symptom scoring (P = 0.01) were significantly decreased with rabeprazole in comparison to esomeprazole. The comparative study of all five domains of the QOLARD questionnaire including overall scoring revealed a statistically significant improvement in the rabeprazole group. Endoscopic findings in the rabeprazole group showed an absolute improvement of 30% and relative improvement of 55% over esomeprazole. Both the drugs were well tolerated having no significant difference in the incidence of adverse effects.Conclusion:Rabeprazole (40 mg) is a better choice for mild-to-moderate GERD compared with esomeprazole (40 mg) because of its better efficacy and safety profile.

Expert Opinion on the Prescription Practice of Rabeprazole and Other Common Proton Pump Inhibitors for Patients with Gastroesophageal Reflux Disease

“…Another randomized clinical trial concluded that rabeprazole 20 mg is non-inferior to esomeprazole 20 mg in treating heartburn and regurgitation symptoms in GERD symptoms [18]. However, a randomized single-blinded study reported that rabeprazole 40 mg has better efficacy when compared to esomeprazole 40 mg in mild-to-moderate GERD patients [19]. These findings underscore a favourable aspect of rabeprazole 20 mg as a treatment option for GERD, as it appears to provide symptom relief without causing additional disruptions in stomach function or hormone levels.…”

Expert Opinion on the Utilization of Proton Pump Inhibitors for the Treatment of Gastroesophageal Reflux Disease among Indian Patients

“…On the other hand, a randomized clinical trial concluded that rabeprazole 20 mg was non-inferior to esomeprazole 20 mg in treating heartburn and regurgitation symptoms in GERD patients [18]. However, a randomized single-blinded study reported that rabeprazole 40 mg has better efficacy when compared to esomeprazole 40 mg in mild-to-moderate GERD patients [19].…”

Efficacy and Safety of Rabeprazole in Children (1–11 Years) With Gastroesophageal Reflux Disease

“…The selected doses are known to be therapeutically effective and safe in adults (15) and adolescents (16), and the highest dose used in this study did not exceed the maximum labeled adult dose (20‐mg dose). Dose selection was based on earlier studies that demonstrated that the known target range for plasma level of exposure (area under the curve, AUC) of rabeprazole for therapeutic acid suppression in adults and adolescents treated with 10‐ and 20‐mg rabeprazole was 400 to 800 ng · h −1 · L −1 (17).…”